Lyell Immunopharma, Inc.

About Lyell Immunopharma, Inc.

Lyell Immunopharma is a clinical-stage company focused on advancing next-generation CAR T-cell therapies to deliver transformative treatments for patients with cancer, particularly targeting solid tumors and hematologic malignancies.

Products & Services

CAR T-Cell Therapies:Designed to generate more durable outcomes for cancer patients, targeting hematologic malignancies and solid tumors with significant unmet medical needs.

Specialties

CAR T-Cell Therapies Oncology Hematologic Malignancies Solid Tumors

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Private Placement T: - FT: Equity Private Placement	A: 100000000 MR: - FA: up to $100 million FAN: 100000000	D: 2025-07-25 FD: 2025-07-25	1 investors

Equity Private Placement Latest

2025-07-25

$100.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Lynn Seely

President & Chief Executive Officer

J

Jarrad Aguirre

Senior Vice President, Medical Affairs

S

Stephen Hill

Chief Operating Officer

G

Gary Lee

Chief Scientific Officer

M

Mark Meltz

General Counsel and Corporate Secretary

C

Charles Newton

Chief Financial Officer

View 21 more team members with Pro

Unlock Full Team Directory

Recent News